#China #Hong Kong #Ascletis #ASC30 #Obesity Webinar

Ascletis Pharma to Innovate Obesity Treatments

Ascletis Pharma Inc., listed on the Hong Kong Stock Exchange under the ticker HKEX:1672, has announced an exciting upcoming event for healthcare professionals and stakeholders interested in obesity management. On April 2, 2025, from 9:00 a.m. to 10:30 a.m. Eastern Time, Ascletis will host a virtual webinar focused on its innovative obesity portfolio.

The webinar will spotlight key advancements in Ascletis' obesity treatment pipeline, particularly its leading candidate: ASC30. This small molecule agonist of GLP-1R has shown significant promise as a best-in-class therapeutic. Participants will gain insights into the efficacy data surrounding two modes of administration for ASC30: a once-daily oral tablet and a once-monthly subcutaneous injection. This dual approach aims to provide versatility and convenience for patients facing obesity challenges.

Leading the discussion will be Jinzi Jason Wu, Ph.D., the Founder and Chief Executive Officer of Ascletis, alongside John Gargiulo, MBA, the Chief Business Officer. The webinar will include a comprehensive presentation followed by a Q&A session, allowing attendees to engage directly with the organization's leadership and explore specific aspects of the obesity treatment strategies.

Registration Details

To attend this enlightening discussion, interested participants are encouraged to register ahead of time. Registration can be completed through a designated link provided on Ascletis' official webpage. The opportunity to view an archived replay of the webinar will also be available for 30 days post-event, ensuring that those who cannot attend live will still benefit from the shared knowledge.

About Ascletis Pharma Inc.

Ascletis is recognized as an innovative biotechnology firm dedicated to addressing critical healthcare needs with a strong research and development focus. With a commitment to treating medical conditions that lack effective solutions, Ascletis operates within two primary therapeutic areas: metabolic diseases and viral diseases. The company is driven by a robust pipeline of clinical-stage drug candidates, which manifest its comprehensive approach to drug development—from discovery to manufacturing.

Ascletis aims to revolutionize how metabolic diseases, particularly obesity, are managed through cutting-edge biopharmaceutical solutions. The webinar represents an opportunity for healthcare professionals to become acquainted with groundbreaking methodologies and promising avenues in obesity treatment, a pressing issue impacting millions worldwide.

For more detailed information about Ascletis and its upcoming events, visit www.ascletis.com or reach out via their contact channels provided on the website. For immediate inquiries, the Ascletis PR and IR teams can be reached at their corresponding email addresses, ensuring timely communication with interested parties.

As a leader in pioneering drug development, Ascletis is committed to transforming lives through advanced science and medicine. Their continuous efforts in research and dedication to patient-centric solutions position them at the forefront of the healthcare industry, especially in combating obesity-related health challenges.